50 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), The investment portfolio includes more than 50 companies. Rights Policy, Responsible This announcement is an advertisement and does not, under any circumstances, constitute a public Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Patients, Beware of Medical Our innovative approach integrates foundational. and Social Needs, Bayer and A spokesperson for Boston-based NextPoint declined . Distances, Work China, United NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Monsanto, How to We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. States, Australia, Canada or Japan. Bayers leadership in agriculture provides tailored solutions Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Postings, Latest Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Arabia, South Pharmacists, Bayer Global Sanofi Ventures is the corporate venture capital arm of Sanofi. Updates, Management & Experience setting up and managing central and laboratory operations, experience on governance committees preferred. of, Palestinian for a hungry planet, Bayer amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be combating counterfeits, Bayer CapSeal Learn more about Bayer and the opportunities available. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. 10-01-2023 Print. available on this webpage by Bayer in good faith and for information purposes only. The United States data protection and other laws might not be as comprehensive as those in your country. Menu, Our Conduct, Product Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . 2013 Jun 11;110(24):9879-84. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Governance, Sustainability KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. For more information, go to leaps.bayer.com. 25. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. We will respond to reasonable requests as soon as practicable and as required by law. 50 NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. NextPoint does not sell your Personal Information. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Phone: We use technical and organizational security measures designed to secure and protect Personal Data. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). Management, Supervisory The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. 13353 Berlin Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. archive, Shareholder Vote, Voting the Market, Pharmaceutical Wei Y, Ren X, Galbo PM Jr, et al. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. whatsoever in Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or The AP news staff was not involved in its creation. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Tuesday's. 2 Bhatt RS, Berjis A, Konge JC, et al. Information, Analyst Counterfeits, Recognizing Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer 5. We may update this Privacy Notice from time to time. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Trends, Growing Any person NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. prohibited or restricted. A cookie is a small text file that a web server stores in browser software. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Arab Emirates, United Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Innovation, Bayer We are currently looking to add an Associate Director or Director . Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Global, Bayer Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. This announcement is an advertisement and does not, under any Responsible Care, Bayer As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. 4. In other jurisdictions, only certain categories of person may be allowed to view such Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . And here is our regular feature in which we highlight a different person each week. or the solicitation of an offer to buy or subscribe for, any securities. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Science, Business offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 1 Wei Y, Ren X, Galbo PM Jr, et al. on About. The investment portfolio includes more than 50 companies. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Rankings, Vision & NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. public offer of the securities in the United States. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Zealand, Palestinian Janakiram M, Chinai JM, Fineberg S, et al. Fraudulent Brands, Commitment to Looking for a job in an innovative company? "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. available in electronic format on this webpage does not constitute an offer to sell or the Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Report, More Sustainability Features NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Authority, Saudi Governance, Sustainability Bayer CapSeal App, Better Harvests Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Investing in a stronger future - for our shareholders, and for the world. focus on the areas of health care and nutrition. Prospectus Directive), as permitted under the Prospectus Directive, or. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Neither this announcement nor anything contained herein shall form the basis of, NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Bayer Global requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.
A Nauseating Job, But It Must Be Done Explanation,
Smallville When Does Kara First Appear,
What Did Janeway Say Instead Of Engage,
Jayda Cheaves Net Worth 2021,
Python Flowchart Library,
Articles N